H2A.Z-dependent crosstalk between enhancer and promoter regulates Cyclin D1 expression
H2A.Z association with specific genomic loci is thought to contribute to a chromatin structure that promotes transcription activation. Acetylation of H2A.Z at promoters of oncogenes has been linked to tumorigenesis. The mechanism is unknown. Here, we show that in triple negative breast cancer cells,...
Gespeichert in:
Veröffentlicht in: | Oncogene 2013-09, Vol.32 (36), p.4243-4251 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | H2A.Z association with specific genomic loci is thought to contribute to a chromatin structure that promotes transcription activation. Acetylation of H2A.Z at promoters of oncogenes has been linked to tumorigenesis. The mechanism is unknown. Here, we show that in triple negative breast cancer cells, H2A.Z bound to the promoter of the constitutively, weakly expressed
cyclin D1
oncogene (
CCND1
), a key regulator of cellular proliferation. Depleting the pool of H2A.Z stimulated transcription of
CCND1
in the absence of its cognate transcription factor, the estrogen receptor (ER). During activation of
CCND1
, H2A.Z was released from the transcription start site (TSS) and downstream enhancer (enh2) sequences. Concurrently, acetylation of H2A.Z, H3 and H4 at the TSS was increased but only H2A.Z was acetylated at enh2. Acetylation of H2A.Z required the Tip60 acetyltransferase to be associated with the activated
CCND1
on both TSS and enh2 sites. Depletion of Tip60 prevented
CCND1
activation. Chromosome conformation capture experiments (3C) revealed specific contacts between the TSS and enh2 chromatin regions. These results suggest that release of a histone H2A.Z-mediated repression loop activates
CCND1
for transcription. Our findings open new avenues for controlling and understanding aberrant gene expression associated with tumorigenesis. |
---|---|
ISSN: | 0950-9232 1476-5594 |
DOI: | 10.1038/onc.2012.442 |